Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The overall aim of the study is to determine the clinical efficacy and mechanisms of action
of anti-IL-4a (dupilumab) as treatment for patients with Aspirin-Exacerbated Respiratory
Disease (AERD).
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)